97 results
8-K
EX-99.1
ATHA
Athira Pharma Inc
17 May 24
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
5:00pm
materials have been posted to the Investor Relations section of Athira’s website (http://investors.athira.com/): the Zoom meeting information for the final
DEFA14A
ATHA
Athira Pharma Inc
9 Apr 24
Additional proxy soliciting materials
8:34am
Materials
Soliciting Material under §240.14a-12
ATHIRA PHARMA, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy … materials
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
PRE 14A
ATHA
Athira Pharma Inc
28 Mar 24
Preliminary proxy
8:47am
Additional Materials
☐ Soliciting Material under §240.14a-12
ATHIRA PHARMA, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s … with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
PRELIMINARY PROXY
8-K
EX-10.1
o4re5i
22 Feb 24
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
4:10pm
8-K
EX-10.1
n2p7 liav03
8 Jan 24
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
7:11am
8-K
EX-10.3
k1as7sildf9r2komc6cf
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
DEFA14A
yn78gj8o5c33xpj15
5 Apr 23
Additional proxy soliciting materials
7:18am
DEFA14A
6qh 5vn076ha
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
6fpw c0axmd08dg1cp
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
5iuzq lx3
16 May 22
Additional proxy materials by non-management
2:04pm
DFAN14A
EX-99.1
m626xt0gjd
16 May 22
Additional proxy materials by non-management
2:04pm